Coexpression of p53 and tissue transglutaminase genes in human normal and pathologic adrenal tissues

Journal of Steroid Biochemistry and Molecular Biology

Volumn 66, Issue 1-2, 1998, Pages 27-33

  Adleff, Vilmos ^a   Rácz, Károly ^a   Szende, Béla ^a   Tóth, Miklós ^a   Moldvay, Judit ^a   Varga, Ibolya ^a   Bezzegh, Attila ^b   Szegedi, Zsolt ^a   Gláz, Edit ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL DISEASE; ARTICLE; CONTROLLED STUDY; CUSHING DISEASE; CUSHING SYNDROME; GENE EXPRESSION; HUMAN; HUMAN TISSUE;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ALDOSTERONE; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; RNA, MESSENGER; TRANSGLUTAMINASES; TUMOR SUPPRESSOR PROTEIN P53;

EUKARYOTA; LIA;

EID: 0032125656     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00004-1     Document Type: Article

References (36)

1. 1. Glicquel C., Bertagna X. and LeBouc Y., Recent advances in the pathogenesis of adrenocortical tumours. Eur. J. Endocrinol. 133 (1995) 133-144.
2. 2. Yano T., Linehan M., Anglard P., Lerman M. I., Daniel L. N., Stein C. A., Robertson C. N., LaRocca R. and Zbar B., Genetic changes in human adrenocortical carcinomas. J. Natl. Cancer Inst. 81 (1989) 518-523.
3. 3. Ohgaki H., Kleihues P. and Heitz P. U., P53 mutations in sporadic adrenocortical tumors. Int. J. Cancer 54 (1993) 408-410.
4. 4. Lin S.-R., Lee Y.-J. and Tsai J.-H., Mutations of the p53 gene in human functional adrenal neoplasms. J. Clin. Endocrinol. Metab. 78 (1994) 483-491.
5. 5. Reincke M., Karl M., Travis W. H., Mastorakos G., Allolio B., Linehan H. M. and Chrousos G. P., P53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 78 (1994) 790-794.
6. 6. Reincke, M., Travis, W. and Chrousos, G. P., Immunohistochemical evidence for p53 mutations in human adrenal carcinomas. Exp. Clin. Endocrinol. 1993, 101(Suppl. 1), 176(Abstr).
7. 7. Lu S., Saydak M., Gentile V., Stein J. P. and Davies P., Isolation and characterization of the human tissue transglutaminase gene promoter. J. Biol. Chem. 270 (1995) 9748-9756.
8. 8. Szende B., Schally A. V. and Lapis K., Immunocytochemical demonstration of tissue transglutaminase indicative of programmed cell death (apoptosis) in hormone sensitive mammary tumours. Acta Morphol. Hung. 39 (1991) 53-58.
9. 9. Sasano H., Imatani A., Souichirou S., Suzuki T. and Nagaura H., Cell proliferation and apoptosis in normal and pathologic human adrenals. Mod. Pathol. 8 (1995) 11-17.
10. 10. Wolkersdöfer G. W., Marx C., Brown J. W., Scherbaum W. A. and Bornstein S. R., Evaluation of apoptotic parameters in normal and neoplastic human adrenal. Endocrinol. Res. 22 (1996) 411-419.
11. 11. Chirgwin J. M., Przybyla A. E., MacDonald R. J. and Rutter W. J., Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18 (1979) 5294-5299.
12. 12. Chomczynki P. and Saachi N., Single step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159.
13. 13. Rácz K., Pinet F., Marton T., Szende B., Gláz E. and Corvol P., Expression of steroidogenic enzyme messenger ribonucleic acids and corticosteroid production in aldosterone-producing and "non-functioning" adrenal adenomas. J. Clin. Endocrinol. Metab. 77 (1993) 677-682.
14. 14. Baker S. J., Markowitz S., Fearon E. R., Willson J. K. and Vogelstein B., Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249 (1990) 912-915.
15. 15. Gentile V., Saydak M., Chiocca E. A., Akande O., Birckbichler P. J., Lee K. N., Stein J. P. and Davies P. J. A., Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases. J. Biol. Chem. 266 (1991) 478-483.
16. 16. Borg A., Lennerstrand J., Stenmark-Askmalm M., Fernö M., Brisfors A., Öhrvik A., Stal O., Killander D., Lane D. and Brundell J., Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br. J. Cancer 71 (1995) 1013-1017.
17. 17. Piacentini M., Annicchiarico-Petruzzelli M., Oliverio S., Piredda L., Biedler J. L. and Melino M., Phenotype-specific "tissue" transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: correlation with cell death by apoptosis. Int. J. Cancer 52 (1992) 271-278.
18. 18. Oren M., Bienz B., Givol D., Rechavi G. and Zakut R., Analysis of recombinant cDNA clones specific for the murine p53 cellular tumor antigen. EMBO J. 2 (1983) 1633-1639.
19. 19. Mukhopadhyay, T., Maxwell, S. A. and Roth J. A., p53 suppressor gene. Springer, Heidelberg, 1995, p. 13.
20. 20. Suto N., Ikura K. and Sasaki R., Expression induced by interleukin-6 of tissue-type transglutaminase in human hepatoblastoma HepG2 cells. J. Biol. Chem. 268 (1993) 7469-7473.
21. 21. Miyashita T., Harigai M., Hanada M. and Reed J. C., Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54 (1994) 3131-3135.
22. 22. Wu X., Bayle J. H., Olson D. and Levine A. J., The p53-mdm-2 autoregulatory feedback loop. Genes and Dev. 7 (1993) 1126-1132.
23. 23. Momand J., Zambetti G. P., Olson D. C., George D. and Levine A. J., The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245.
24. 24. Velculescu V. E. and El-Deiry W. S., Biological and clinical importance of the p53 tumor suppressor gene. Clin. Chem. 42 (1996) 858-868.
25. 25. Kastan M. B., Onyerkvere O., Sidransky D., Vogelstein B. and Craig R. W., Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 53 (1991) 6304-6311.
26. 26. Shaw P., Bovey R., Tardy S., Sahli R., Sordat B. and Costa J., Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4495-4499.
27. 27. Wyllie A. H., Apoptosis: cell death in tissue regulation. J Pathol. 153 (1987) 313-316.
28. 28. Fesus L., Thomazy V. and Falus A., Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett. 224 (1987) 104-108.
29. 29. Piacentini M., Fesus L., Farrace M. G., Ghibelli L., Piredda L. and Melino G., The expression of "tissue" transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis). Eur. J. Cell. Biol. 54 (1991) 246-254.
30. 30. Aeschlimann D. and Paulsson M., Transglutaminases: protein cross-linking enzymes in tissues and body fluids. Thrombosis and Haemostasis 4 (1994) 402-415.
31. 31. Hollstein M., Sidransky D., Vogelstein B. and Harris C. C., p53 mutations in human cancers. Science 253 (1991) 49-53.
32. 32. Dahia P. L. M., Aguiar R. C. T., Tsanaclis A. M., Bendit I., Bydlowski S. P., Abelin N. M. A. and Toledo S. P. A., Molecular and immunohistochemical analysis of p53 in pheochromocytoma. Br. J. Cancer 72 (1995) 1211-1213.
33. 33. Bodner S. M., Minna J. D. and Jensen S. M., Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutations. Oncogene 7 (1992) 753-759.
34. 34. Sherley J. L., Guanine nucleotide biosynthesis is regulated by the cellular p53 concentration. J. Biol. Chem. 266 (1991) 24815-24828.
35. 35. Hildesheim A., Herrero R., Johnson J., Bratti C., Bhatia K., Magrath I. T. and Fraumeni J. F. Jr., Elevated levels of p53 protein in adrenocortical carcinomas from Costa Rica. Eur. J. Cancer 31A (1995) 125.
36. 36. Prioleau J. and Schnitt S. J., p53 antigen loss in stored paraffin slides. New Eng. J. Med. 332 (1995) 1521.